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T he  pu r po se  o f t he  T r e nt  D e ve lo pm e nt  and E valu at io n C o m m it t e e  is t o  he lp he alt h au t ho r it ie s 
and o t he r  pu r c hase r s wit hin t he  T r e nt  R e gio n b y c e m e nt ing o n e xpe r t  r e po r t s whic h 
e valu at e  c hange s in he alt h se r vic e  pr o visio n. T he  C o m m it t e e  is c o m pr ise d o f m e m b e r s 
appo int e d o n t he  b asis o f t he ir  individu al kno wle dge  and e xpe r t ise . I t  is c hair e d b y P r o fe sso r  
S ir  D avid H u ll.
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T he  C o m m it t e e  r e c o m m e nds, o n t he  b asis o f e vide nc e  pr o vide d, pr io r it ie s fo r : 
o  t he  dir e c t  de ve lo pm e nt  o f inno vat ive  se r vic e s o n a pilo t  b asis; 
0  se r vic e  de ve lo pm e nt s t o  b e  se c u r e d b y he alt h au t ho r it ie s. 
T he  st at e m e nt  t hat  fo llo ws was pr o du c e d b y t he  D e ve lo pm e nt  and E valu at io n C o m m it t e e  at
it s m e e t ing o n 10  O c t o b e r  2 0 0 0  at  whic h t his G u idanc e  N o t e  fo r  P u r c hase r s (in a dr aft  fo r m ) 
was c o nside r e d. 
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L e ic e st e r shir e  H alt h A u t ho r it y), M r  P  G o light ly (D ir e c t o r , T r e nt  D r u g I nfo r m at io n S e r vic e s), 
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F O R E W O R D  
T he  T r e nt  W o r king G r o u p o n A c u t e  P u r c hasing was se t  u p t o  e nab le  pu r c hase r s t o  shar e  
r e se ar c h kno wle dge  ab o u t  t he  e ffe c t ive ne ss and c o st - e ffe c t ive ne ss o f ac u t e  se r vic e  
int e r ve nt io ns and de t e r m ine  c o lle c t ive ly t he ir  pu r c hasing po lic y. T he  G r o u p is fac ilit at e d b y 
T he  S c ho o l o f H e alt h and R e lat e d R e se ar c h (S c H A R R ), par t  o f t he  T r e nt  I nst it u t e  fo r  H e alt h 
S e r vic e s R e se ar c h, t he  S c H A R R  S u ppo r t  T e am  b e ing le d b y P r o fe sso r  R o n A ke hu r st . 
T he  pr o c e ss e m plo ye d o pe r at e s a  fo llo ws. A  list  o f t o pic s fo r  c o nside r at io n b y t he  G r o u p is 
r e c o m m e nde d b y t he  pu r c hasing au t ho r it ie s in T r e nt  and appr o ve d b y t he  H e alt h A u t ho r it y 
and T r u st  C hie f E xe c u t ive s (H A T C H ) and t he  T r e nt  D e ve lo pm e nt  and E valu at io n C o m m it t e e  
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S U M M A R Y  
E vide nc e  fo r  t he  e ffe c t ive ne ss, c o st — e ffe c t ive ne ss, and safe t y o f c u r r e nt ly availab le  o r al 
ant iplat e le t  age nt s (aspir in (A S A ), dipyr idam o le , c lo pido gr e l, and t ic lo pidine ) fo r  t he  pr e ve nt io n 
o f st r o ke  and o t he r  se r io u s vasc u lar  e ve nt s in pat ie nt s at  high vasc u lar  r isk is pr e se nt e d. 
A t he r o sc le r o sis o f t he  ar t e r ial walls is t he  u nde r lying ae t io lo gy c o m m o n t o  all t he  c o ndit io ns 
u nde r  r e vie w, t hat  is, t r ansie nt  isc hae m ic  at t ac k (T I A ), isc hae m ic  st r o ke  (I S ), c o r o nar y he ar t  
dise ase  (C H D ), and pe r iphe r al ar t e r ial dise ase  (P A D ). C alc u lat ing t he  o ve r all pr e vale nc e  o f 
at he r o sc le r o t ic  dise ase  in t he  po pu lat io n is har d t o  e st ab lish, as m any o f t ho se  affe c t e d ar e  
asym pt o m at ic . H o w e ve r , it  is e st im at e d t hat  t he  pr e vale nc e  o f sym pt o m at ic  dise ase  in t he  
T r e nt  R e gio n lie s b e t w e e n 12 7,0 0 0  and 185,0 0 0 . I n an ave r age  he alt h dist r ic t  o f 50 0 ,0 0 0  
r e side nt s it is e st im at e d t hat  12 ,40 0 - 18,0 0 0  pe o ple  ar e  affe c t e d. 
F o r  t ho se  who  c an t o le r at e  it , t he  e vide nc e  t hat  A S A  sho u ld r e m ain t he  fir st  line  t r e at m e nt  fo r  
t he  pr e ve nt io n o f st r o ke  and o t he r  se r io u s vasc u lar  e ve nt s is st r o ng. U nt il fac ilit ie s fo r  t e st ing 
A S A  do se - r e spo nsive ne ss ar e  m o r e  wide ly availab le , pr e se nt  e vide nc e  indic at e s t he  do se  o f 
75m g daily t o  o pt im ise  t he  se c o ndar y pr e ve nt io n o f st r o ke  and se r io u s vasc u lar  e ve nt s, whilst  
m inim ising t he  r isk o f gast r o int e st inal (G I ) side - e ffe c t s. A lt ho u gh A S A  is e ffe c t ive  and 
ine xpe nsive , int o le r anc e  is t he  m ain r e aso n fo r  c o nside r ing se c o nd line  t he r apy. T he  pr e c ise  
le ve l o f A S A  se nsit ivit y/int o le r anc e  is u nkno wn alt ho u gh G I  int o le r anc e  r ange s fr o m  2 - 2 0 %  
(do se - r e lat e d). O pt io ns fo r  t he  r e du c t io n o f int o le r anc e  inc lu de  lo w e r ing do sage , pr e sc r ib ing 
e nt e r ic — c o at e d (E C ) A S A , o r  c o — pr e sc r ib ing ac id- su ppr e ssant  t he r apy. T he  e ffe c t ive ne ss o f 
A S A  fo r  G I  int o le r anc e  fo r  t he  lat t e r  o pt io n is u nkno wn, sinc e  all t he  t r ial e vide nc e  is fo r  no n-  
st e r o idal ant i- inflam m at o r y dr u gs (N S A I D s). R o u t ine  ac id- su ppr e ssant  t he r apy is no t  indic at e d 
fo r  pat ie nt s t aking aspir in and, if t his t he r apy is give n t o  pat ie nt s wit h gast r ic  side - e ffe c t s fr o m  
aspir in, t he n it  sho u ld b e  disc o nt inu e d if t he r e  is. no  im pr o ve m e nt  in sym pt o m s. 
D ipyr idam o le  m ay b e  c o nside r e d fo r  I S  and T I A  pat ie nt s u nab le  t o  t o le r at e  A S A , ho w e ve r , t he  
m ain phar m ac o lo gic al m e c hanism s o f dipyr idam o le  ar e  no t  fu lly u nde r st o o d. T he  E S P S - 2  
st u dy su gge st s t hat  dipyr idam o le  and A S A  have  sim ilar  e ffic ac y, and t hat  whe n pr e sc r ib e d in 
c o m b inat io n, t he r e  is an addit ive  e ffe c t . T he  vie w  o f c linic ians o n t he  validit y o f t he  E S P S — 2  
st u dy, ho w e ve r , r e m ains divide d. T he  R o yal C o lle ge  o f P hysic ians’ (R C P ) G u ide line s o n S t r o ke  
r e c o m m e nd c o m b ine d lo w  do se  A S A  and m o difie d r e le ase  dipyr idam o le  fo r  fir st  line  t he r apy, 
and dipyr idam o le  fo r  se c o nd line  t he r apy. T he se  R C P  gu ide line s ar e  no t  applic ab le  t o  o t he r  
t ype s o f sym pt o m at ic  at he r o sc le r o t ic  dise ase  c o ve r e d b y t his r e po r t .
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2 . BA C K G R O U N D  
2 .1 U N D E R L Y I N G  D I S E A S E  F O R  W H I C H  A N T I P L A T E L E T  T H E R A P Y  I S  A P P R O P R I A T E  
2 .1.1 A e t io lo gy 
A nt iplat e le t  t he r apy is a u se fu l m e ans o f pr e ve nt ing ac u t e  t hr o m b o - e m b o lic  ar t e r y o c c lu sio ns in 
pat ie nt s at  inc r e ase d vasc u lar  r isk.1 H o w e ve r , c ar dio vasc u lar  dise ase  c an pr e se nt  in a var ie t y 
o f ways. T his r e po r t  fo c u se s o n I S , M I , and P A D  and t he  e vide nc e  fo r  t he ir  pr e ve nt io n b y 
ant iplat e le t  t he r apy. 
T he  u nde r lying ae t io lo gy is c o m m o n t o  all t he se  c o ndit io ns. T hat  is, at he r o sc le r o t ic  plaqu e s o n 
t he  ar t e r ial walls m ay b r e ak o ff and b e c o m e  t he  sit e  fo r  t he  de ve lo pm e nt  o f a t hr o m b u s. T his 
wo u ld fu r t he r  nar r o w  t he  ar t e r y. T he  sym pt o m s var y, de pe nding o n t he  par t  o f t he  vasc u lar  
syst e m  affe c t e d. T hu s, st r o ke , M I  o r  P A D  c an r e su lt  and t ho se  at  r isk o f o ne  ar e  like ly t o  b e  at  
r isk o f t he  o t he r s.2  
2 .1.2  E pide m io lo gy 
T he  pr e vale nc e  o f c ar dio vasc u lar  dise ase  is har d t o  e st ab lish, as sym pt o m at ic  dise ase  is ju st  
t he  t ip o f t he  ic e b e r g and t he  e xt e nt  o f asym pt o m at ic  dise ase  is u nc e r t ain. H o w e ve r , t he  
sym pt o m at ic  c o ndit io ns pr o vide  an e st im at e  o f t ho se  in ne e d o f t he  he alt h se r vic e s. T ab le 1 
su m m ar ise s t he  pr e vale nc e  o f sym pt o m at ic  dise ase  in t he  c o m m u nit y. N o  st u die s we r e  fo u nd 
o n t he  pr e vale nc e  o f pe o ple  who  have  had T I A . H o w e ve r , t he  inc ide nc e  is r e po r t e d t o  b e  0 .42  
pe r  1,0 0 0  po pu lat io n pe r  ye ar .3 W it hin t he  T r e nt  R e gio n t his wo u ld b e  2 ,150  T I A  e ve nt s 
annu ally and, in a he alt h dist r ic t  o f 50 0 ,0 0 0  po pu lat io n, 2 10  annu ally. 
C alc u lat ing t he  o ve r all pr e vale nc e  o f at he r o sc le r o t ic  dise ase  fr o m  t he  figu r e s in T ab le  1 c o u ld 
pr o vide  an inac c u r at e  e st im at e  o f t he  nu m b e r s o f pe o ple  invo lve d fo r  t he  fo llo wing r e aso ns. 
T I A  pr e vale nc e  is e xc lu de d. D u e  t o  t he  o ve r lap o f I S , C H D  and P A D  wit hin individu als, t he r e  
wo u ld b e  do u b le  (o r  t r iple ) c o u nt ing o f an u nkno wn pr o po r t io n o ft he  at he r o sc le r o t ic  po pu lat io n. 
P e o ple  wit h asym pt o m at ic  at he r o sc le r o t ic  dise ase  ar e  e xc lu de d, b u t  m ay b e ne fit  fr o m  
int e r ve nt io n wit h ant iplat e le t  t he r apy.
b ) M o r b idit y 
I n addit io n t o  pr e ve nt ab le  m o r t alit y, a lar ge  pr o po r t io n o f pat ie nt s who  have  had a m ajo r  
vasc u lar  e ve nt  su ffe r  fr o m  lo ng- t e r m  o r b idit y and disab ilit y as a r e su lt . T he y also  have  an 
inc r e ase d r isk o f fu r t he r  m ajo r  vasc u lar  e ve nt s. ‘S aving L ive s: O u r  H e alt hie r  N at io n’8 r e po r t s 
t hat : 
. C H D  is an im po r t ant  c au se  o f disab ilit y - —  o ne  in 2 0  pe o ple  r e po r t ing se r io u s disab ilit y 
ide nt ifie s C H D  as a c au se . 
. S t r o ke  is t he  se c o nd m o st  im po r t ant  c au se  o f e xpe ndit u r e  o n c o m m u nit y he alt h and 
so c ial c ar e  fo r  adu lt s —  ac c o u nt ing fo r  o ve r  7%  o f su c h e xpe ndit u r e . 
P A D  c au se s pain and disab ilit y fr o m  int e r m it t e nt  c lau dic at io n. U lt im at e ly, lo w e r  lim b  am pu t at io n 
m ay b e  r e qu ir e d whic h wo u ld r e su lt  in fu r t he r  disab ilit y and e ve n gr e at e r  inpu t  fr o m  t he  
disab ilit y se r vic e s. 
2 .1.4 O r al A nt iplat e le t  T he r apie s fo r  D isc u ssio n 
T he  o r al ant iplat e le t  t he r apie s fo r  t he  pr e ve nt io n o f se r io u s vasc u lar  e ve nt s b e ing c o nside r e d 
he r e  inc lu de  A S A , whic h is an age - o ld r e m e dy fo r  m any ills wit h pr o ve n e ffic ac y fo r  it s 
ant iplat e le t  e ffe c t , D P , and ne w e r  t hie no pyr idine  de r ivat ive sf”10  D P  has b e e n u se d alo ne  o r  in 
c o m b inat io n wit h A S A . T he  t hie no pyr idine  de r ivat ive s ar e  m o r e  r e c e nt  and inc lu de  t ic lo pidine  
and c lo pido gr e l. T he se  dr u gs ac t  in diffe r e nt  ways t o  inhib it  plat e le t  aggr e gat io n. T he y will b e  
disc u sse d fu r t he r  in t he  fo llo wing se c t io ns. 
T he r e  ar e  o t he r  o r al age nt s in de ve lo pm e nt , whic h inc lu de  lo t r afib an, he par in o r al- E m isphe r e , 
L D P  O 1, C ilo st azo l and dipyr idam o le  e xt e nde d r e le ase /aspir in. T he se  ar e  no t  inc lu de d b e c au se  
t he  r e le vant  r e se ar c h is no t  ye t  availab le . 
T ab le  2  pr e se nt s t he  t r e at m e nt  c o st s o f c u r r e nt  o r al ant iplat e le t  age nt s. 
i:
g
2 .2  D R U G  I N T E R V E N T I O N S  
F igu r e  1 illu st r at e s t he  sit e s o f ac t io n o f diffe r e nt  plat e le t  inhib it o r s. S o u r c e  give n b e lo w. 
F igu r e  1 S it e s o f A c t io n o f D iffe r e nt  P lat e le t  I nhib it o r s 
R u pt u r e d A t he r o sc le r o t ic  plaqu e  
C o llage n T hr o m b in 
A c t ivat io n o f plat e le t s 
1:1A S A :b 1¢¢K si :i:
Z- ZS Y t hhG S iS - O fi ~i~ 
fihf9fr ib 95<ér i¢fizi 
- f- b Y ~ P 'fle ie ft S G f 
P lat e le t  
P lat e le t  r e le ase  o f dr e le age  0 ;, P lat e le t  
t hr o m b o xane  A 2  a. 
e no sm e  ' c o agu lant  
dlspho sphat e  
ac t ivit y 
(A D P ) 
T ic 1¢b idiné:o _r i sslsspr ism gr e r l , 
E iD N b it A D P  I b lniding 19%  T hr o m b in 
:ir ¢¢épiér 19hiplat ét ét $:i: ge ne r at io n 
C o nfo r m at io nal ac t ivat io n o f plat e le t  glyc o pr o t e in 11b /111a 
r e c e pt o r s o n plat e le t  su r fac e  
1:3fG iyb épr ét éin3131b /131:1ézér it é99hi5fs?:3: 
: inhib it . plat e le t . aggr e gat io n. b y. b lo c king:. 
:2 :::fib r ihb ge inr m ndm gt t dac t ivat e dI :I zizr  
P lat e le t  aggr e gat io n 
(S o u r c e : H ir sc h and W e it z1999") 
*T he se  age nt s ar e  no r m ally int r ave no u s and ar e  no t  inc lu de d in t his r e po r t . D P  is no t  inc lu de d 
in t his diagr am , as, alt ho u gh it s ant iplat e le t  m e c hanism s ar e  u nde r st o o d, t he ir  r e lat ive  
im po r t anc e  has no t  b e e n fu lly de t e r m ine d. I t  is b ase d o n t he  ab ilit y t o  m o dify var io u s aspe c t s o f 
plat e le t  fu nc t io n, su c h as t he  inhib it io n o f plat e le t  adhe sio n and aggr e gat io n. I t  also  le ngt he ns 
plat e le t  su r vival t im e .
3. E F F E C T I V E N E S S  
3.1 M E T H O D S  F O R  R E V I E W I N G  E F F E C T I V E N E S S  
T he  o r iginal M e dline  se ar c hing st r at e gy u nde r t ake n fo r  t his pape r  is pr e se nt e d in t he  A ppe ndix. 
S im ilar  se ar c he s u sing S c ie nc e  C it at io n I nde x and C o c hr ane  dat ab ase s w e r e  also  u nde r t ake n. 
Be c au se  t he  nu m b e r  o f c linic al pape r s ide nt ifie d b y t he se  se ar c he s was no t  o f a m anage ab le  
size , a m o r e  r e st r ic t e d se ar c h fo r  c linic al pape r s, whe r e  t he  ‘pu b lic at io n t ype ’ was r e st r ic t e d t o
'c linic al t r ial' was u se d. 
3.2  R E S U L T S  
3.2 .1 Q u ant it y and Q u alit y o f R e se ar c h A vailab le  
A ppr dxim at e ly 40  pu b lic at io ns we r e  se le c t e d fo r  r e vie w  fo llo wing t he  lit e r at u r e  se ar c h. O f 
t he se , 11 pape r s m e t  t he  aim  o f t his r e po r t  (se e  S e c t io n 1). O f t he se , 11 we r e  se le c t e d fo r  
fu r t he r  analysis. F o u r  o f t he  11 we r e  o r iginal st u die s and se ve n we r e  r e vie ws. T he  de t ails o f 
t he  pape r s ar e  su m m ar ise d in T ab le s 4 and 5 r e spe c t ive ly. T he  r e vie w  ar t ic le s ide nt ifie d we r e  
o f var iab le  qu alit y and o ft e n did no t  indic at e  spe c ific  inc lu sio n o r  e xc lu sio n c r it e r ia. T he  r e vie w  
b y H anke y e t  al.2 5 (C o c hr ane  syst e m at ic  r e vie w) is a high qu alit y r e vie w  whic h ide nt ifie s fo u r  
o r iginal pu b lic at io ns, o ne  c o m par ing A S A  wit h C lo pido gr e l (t he  C A P R I E  st u dy), and t hr e e  
c o m par ing A S A  wit h t ic lo pidine . T he  m e t a- analysis r e su lt s o f t his r e vie w  ar e  give n in T ab le  6.
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T ab le  4 c o nt inu e d 
E L  
1995, 384 c e nt r e s in 
U S A , E u r o pe  & A u st r alia 
A dve r se  e ve nt s C lo pido gr e l A S A  
S kin R ash 0 .2 6%  
' 
0 .1%  
D iar r ho e a 0 .2 3%  0 .11%  
U ppe r  G I  D isc o m fo r t  0 .97%  1.2 2 %  
lnt r ac r anial b le e d 0 .33%  0 .47%  
G l Ble e d 0 .52 %  0 .72 %  
N e u t r o pe nia 0 .1%  0 .17%  
S t r o ke  pat ie nt s —  ave r age  e ve nt  r at e  pe r  
ye ar  fo r  C lo pido gr e l was 7.15%  and 7.71%  
fo r  A S A  (r e lat ive  r isk r e du c t io n (R R R ) 
7.3%  r ange  —  5.748.?) fo r  M l 5.0 3%  and 
4.84%  (r e lat ive  r isk inc r e ase  3.7%  r ange  
2 2 .1-  — 12 .0 ) and fo r  P A D  3.71%  and 
4.86%  (R R R  2 3.8%  -  r ange  8.9— 36.2 ) 
A u t ho r  & T ype , S ize , S e t t ing P u r po se , I nt e r ve nt io n R e su lt s C o m m e nt s 
Y e ar  o f S t u dy A im  o f 
S t u dy 
C A P R I E  R ando m ise d b linde d t r ial C o m par iso n o f C lo pido gr e l 75m g C lo pido gr e l pat ie nt s had annu al r isk o f S t u dy spo nso r e d b y 
S t e e r ing o f 19,185 pat ie nt s (6,431 t he  lo ng- t e r m  daily, A S A  32 5m g 5.32 %  o f I S , M I  and vasc u lar  de at h S ano fi. 
C o m m it t e e  wit h I S , 6,30 2  M l, 6,452  safe t y and daily — -  m inim u m  o f 1 c o m par e d wit h 5.83%  wit h A S A . N o  Br ist o l— M ye r s— S qu ib b  
1996.2  P A D ), age d 2 1 ye ar s o r  t o le r ab ilit y o f ye ar  and m axim u m  diffe r e nc e s in safe t y. R e po r t e d adve r se  
o ve r  wit h sym pt o m at ic  C lo pido gr e l o f 3 ye ar s. r e ac t io ns ju dge d t o  b e  se ve r e  inc lu de d: 
at he r o sc le r o sis —  1992 -  and A S A . 
J W  H ar b iso n e t  
al., 1992 .2 8 
T ic lo pidine  A spir in S t r o ke  
S t u dy (T A S S ) S u b - gr o u p. 
M u lt ic e nt r e  do u b le  b lind 
r ando m ise d t r ial o f 92 7 
pat ie nt s wit h r e c e nt  m ino r ’ 
c o m ple t e d st r o ke  wit hin3 
m o nt hs o f st u dy e nt r y. 
T o  inve st igat e : 
-  F ir st  
o c c u r r e nc e  
o f no n- fat al 
st r o ke , 
-  D e at h, any 
c au se , 
-  F ir st  
o c c u r r e nc e  
o f fat al and 
no n- fat al 
st r o ke  
A S A  650 m g x 2  daily 
O r  
T ic lo pidine  2 50 m gx 
2  daily. 
T ic lo pidine  m o r e  e ffe c t ive  t han A S A  (R R R  
o f 36% ) 
C o nsist e nt  wit h o ve r al! 
T A S S  st u dy —  i.e . 
t ic lo pidine  m o r e  e ffe c t ive  
t han A S A  fo r  r e du c ing 
r isk o f st r o ke  in pat ie nt s 
wit h c o m ple t e d m ino r  
st r o ke .
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T ab le  5 c o nt inu e d 
A u t ho r  & Y e ar  T ype , S ize , S e t t ing o f P u r po se , A im  I nt e r ve nt io n R e su lt s C o m m e nt s 
S t u dy o f S t u dy 
S M  D avis e t  al., R e vie w  ar t ic le  —  2 6 T o  highlight  N o t  applic ab le . T ic lo pidine  o ffe r e d as se c o nd line  t he r apy R e vie w  inc lu de s m any 
1998.30  pape r s. im po r t anc e  o f du e  t o  m ild st at ist ic al b e ne fit  o ve r  A S A , pape r s, b u t  au t ho r s we r e  
ant iplat e le t  inc r e ase d r isk o f se r io u s adve r se  e ve nt s 
‘ 
aske d t o  fo c u s o n 
t he r apy in (e .g. 1%  r e ve r sib le  ne u t r o pe nia r t e ), C A P R I E  and E S P S - 2 . 
st r o ke  ne e d fo r  b lo o d m o nit o r ing and c o st . 
pr e ve nt io n. C lo pido gr e l sho u I d r e plac e  t ic lo pidine  as 
se c o nd line  t he r apy, du e  t o  lac k o f se r io u s 
adve r se  e ffe c t s and c o m par ab le  e ffic ac y, 
b u t  will no t  r e plac e  A S A  as fir st  line  
t he r apy du e  t o  m o de st  su pe r io r it y and 
highe r  c o st . 
W o u ld no t  u se  D P  du e  t o  lac k o f e vide nc e  
in all st u die s e xc e pt  E S P S - Z. 
E S P S  — 2  —  c halle nge d fo r  vio lat io n o f 
e t hic s and fr au d. D o sage  o f A S A  and D P  
diffe r e nt  fr o m  o t he r  st u die s. S t u dy m ay b e  
b iase d in favo u r  o f D P  du e  t o  lo w  A S A  " 
do sage  u se d. 
C anadian 0 0 —  R e vie w  ar t ic le  —  17 C o m par e s N o t  A pplic ab le . A S A  sho u ld r e m ain fir st  line  t he r apy. N o  e xplic it  inc lu sio n/ 
o r dinat ing o ffic e  
fo r  H T A  1999.31 
pu b lic at io ns. e ffic ie nc y and 
c o st  o f 
c lo pido gr e l t o  
A S A /t ic lo pidine  
/D P / 
su lfinpyr azo ne  
fo r  pat ie nt s 
wit h T I A , 
st r o ke , 
u nst ab le  
angina, M I  and 
P A D . 
Bo t h c lo pido gr e l and t ic lo pidine  ar e  m o r e  
e xpe nsive  t han A S A  wit ho u t  signific ant  
advant age  as fir st  line  t he r apy. 
C A P R I E  st u dy -  o nly signific ant  diffe r e nc e  
in R R R  fo r  c lo pido gr e l ve r su s A S A  was fo r  
P A D  (L e . no t  st r o ke  o r  M I ). 
S ide - e ffe c t s: 
-  D yspe psia (18%  A S A , 15%  
c lo pido gr e l) 
-  G I  Ble e d (3%  A S A , 2 %  c lo pido gr e l). 
e xc lu sio n c r it e r ia.
A L  
T ab le  6 S u m m ar y o f M e t a- analysis R e su lt s (H anke y 1999)2 5 
H igh V asc u lar  R isk P at ie nt s A S A  T hie no pyr idine s O dds 95%  C o nfide nc e  C o m m e nt s 
%  %  R at io  int e r val (C I ) 
(0 R ) 
1. S e r io u s V asc u lar  E ve nt s 
S t r o ke , M I , vasc u lar  de at h 13 12  0 .91 0 .84 —  0 .98 11 e ve nt s avo ide d pe r  1,0 0 0  t r e at e d o ve r  2  ye ar s 
S t r o ke s o f all t ype s 6.4 5.7 0 .88 0 .79 —  0 .98 7 e ve nt s avo ide d pe r  1,0 0 0  t r e at e d o ve r  2  ye ar s 
I S  o r  st r o ke  o f u nkno wn t ype  6.1 5.5 0 .90  0 .81 — —  1.0 1 N o n- signific ant  
H ae m o r r hagic  st r o ke  4.0  3.3 0 .82  0 .53 —  1.2 7 N o n- signific ant  
M I  3.9 3.4 0 .88 0 .76 —  1.0 1 N o n— signific ant  
V asc u lar /u nkno wn c au se  o f 4.8 4.5 0 .93 0 .82  —  1.0 6 N o n- signific ant  
de at h du r ing fo llo w  u p 
D e at h fr o m  any c au se  6.8 6.5 0 .95 0 .85 —  1.0 5 N o n- signific ant  
E xt r a —  c r anial hae m o r r hage  8.86 8.84 1.0  0 .91 —  1.0 9 N o n— signific ant  
sit e  inc lu ding G I  
G I  hae m o r r hage  2 .5 1.8 0 .71 0 .59 —  0 .86 
N e u t r o pe nia 0 .8 2 .3 2 .7 1.5 —  4.8 T ic lo pidine  o nly. C lo pido gr e l sim ilar  t o  A S A  
S e ve r e  T hr o m b o c yt o pe nia 0 .10  0 .19 1.77 0 .84 —  3.71 C lo pido gr e l o nly. N o  dat a fo r  t ic lo pidine  
S kin r ash 4.6 6.0  1.3 1.2  —  1.5 -  C lo pido gr e l 
5.5 11.8 2 .2  1.7 —  2 .9 -  T ic lo pidine  
D iar r ho e a 3.4 4.5 1.3 1.2  —  1.6 -  C lo pido gr e l 
9.9 2 0 .4 2 .3 1.9 —  2 .8 —  T ic lo pidine  
I ndige st io n/nau se a/vo m it ing 17.1 14.8 0 .84 0 .78 —  0 .90  
2 . T I A  o r  I S  P at ie nt s v 
S e r io u s vasc u lar  e ve nt s 18.3 16.8 0 .90  0 .81 —  1.0 0  Bo r de r line  signific anc e  
14 e ve nt s avo ide d pe r  1,0 0 0  t r e at e d o ve r  2  ye ar s 
S t r o ke pf all t ype s 12  10 .4 0 .86 0 .75 —  0 .97 16 e ve nt s avo ide d pe r  1,0 0 0  t r e at e d o ve r  2  ye ar s 
lS /st r o ke  o f u nkno wn t ype  11.5 10 .2  0 .87 0 .77 —  0 .99 
H ae m o r r hagic  st r o ke  0 .7 0 .6 0 .87 0 .52  —  1.44 N o  diffe r e nc e  
O t he r  o u t c o m e s S im ilar  t o  t ho se  give n fo r  all high r isk pat ie nt s 
(n = 2 2 ,656 —  T I A  o r  I S  = 9,840 , M I  = 6,30 2 , P A D  = 6,514)
. I t  has no t  b e e n st u die d in pe o ple  wit h a pr e vio u s hist o r y o f A S A  se nsit ivit y. 
0  I t  is no t  kno wn, t he r e fo r e , if c lo pido gr e l wo r ks in A S A - se nsit ive  p o ple  and if t ho se  who  
ar e  A S A - se nsit ive  ar e  also  m o r e  like ly t o  b e  c lo pido gr e l- se nsit ive . 
. I t s o ve r all e ffic ac y (all c au se  m o r t alit y) is no  b e t t e r  t han A S A . 
-  T he  pr o po r t io n o fpat ie nt s who  disc o nt inu e  t r e at m e nt , du e  t o  adve r se  e ve nt s, is e qu al t o  
t hat  o f A S A  (T ab le  7). 
3.3.2  A spir in and D ipyr idam o le  
T he  E S P S — 2  st u dy2 6 su gge st s t hat : 
0  D P  40 0 m g daily and A S A  50 m g daily have  sim ilar  e ffic ac ie s. 
T he r e  is, ho w e ve r , so m e  dispu t e  wit h r e spe c t  t o  t he  u se  o f D P  in t he  lit e r at u r e . T he  R o yal 
C o lle ge  o f P hysic ians’ N at io nal C linic al G u ide line s fo r  S t r o ke 13 do  r e c o m m e nd, ho w e ve r , 
t he  u se  o f a c o m b inat io n o f lo w  do se  A S A  and M R D  fo r  fir st  line  t he r apy, and D P  fo r  se c o nd 
line  t he r apy fo r  st r o ke  pr e ve nt io n. 
O t he r  au t ho r s have  qu e st io ne d t he  E S P S — 2  st u dy30  fo r  vio lat io n o f e t hic s (du e  t o  t he  st u dy 
having a plac e b o  ar m  whe n t he  u se  o f A S A  is b e yo nd qu e st io n) and fr au d b y o ne  
par t ic ipat ing c e nt r e , alt ho u gh t he  lat t e r  was e xc lu de d fr o m  t he  final analysis. H o w e ve r , t he  
e t hic s c o m m it t e e s o f par t ic ipat ing c e nt r e s gave  t he ir  appr o val fo r  t he  st u dy, whic h was no t  
wit hdr awn at  any lat e r  st age  o f t he  r e se ar c h. I n addit io n, t he  do se  o f A S A  u se d in t he  st u dy 
is diffe r e nt  fr o m  t hat  u se d in o t he r  st u die s and is no t , t he r e fo r e , dir e c t ly c o m par ab le . E S P S -  
2 2 6 u se d A S A  2 5m g b .d. and M R D  2 0 0 m g b .d. T he  ar gu m e nt  is t hat  t his do se  m ay have  
r e du c e d t he  po ssib le  b e ne fit  o f A S A , and b iase d t he  r e su lt s in favo u r  o f D P . F o r  t he se  
r e aso ns, whilst  t he  r e su lt s ho u ld no t  b e  dism isse d, t he y sho u ld b e  V ie w e d wit h c au t io n. 
H o w e ve r , t he  o ngo ing E u r o pe an/A u st r alian S t r o ke  P r e ve nt io n in R e ve r sib le  sc hae m ia T r ial 
(E S P R I T ) o ft he  c o — fo r m u lat io n fA S A  and D P  ve r su s A S A  will pr o vide  fu r t he r  info r m at io n. 
3.3.3 A spir in I nt o le r anc e : t he  S ize  o f t he  P r o b le m  
I f A S A  int o le r anc e  is t he  m ain r e aso n fo r  c o nside r ing se c o nd line  t he r apy, it  is im po r t ant  o  
de t e r m ine  ho w  m any pat ie nt s fall int o  t his c at e go r y.
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T ab le  7 O ve r all S afe t y A nalysis —  C A P R I E  S t u dy2  
A dve r se  E ve nt s C lo pido gr e l (n = 9599) A S A  (n = 9586) 
E ar ly pe r m ane nt  disc o nt inu at io n o f 11.94 11.92  
st u dy du e  t o  adve r se  e ve nt s (% ) 
G I  D iso r de r  (% ) 3.2 1 4.0 2  
S kin o r  A ppe ndage  D iso r de r  (% ) 1.52  0 .76 
F at al adve r se  e ve nt  du r ing st u dy dr u g 4.15 4.39 
t r e at m e nt  & 2 8 days aft e r  c e ssat io n (% ). 
A ny G I  b le e d 
A ll 191 (1.99% ) 2 55 (2 .66% ) 
S e ve r e  47 (0 .49% ) 68 (0 .71% ) 
H o spit alise d 71 (0 .74% ) 10 4 (1 .0 8% ) 
F at al 1 (0 .0 1% ) 2  (0 .0 2 % ) 
A ny G I  A dve r se  S ym pt o m s 
A ll 2 7.14%  2 9.82 %  
S e ve r e  2 .98%  3.60 %  
U lc e r  (G ast r ic , P e pt ic , D u o de nal) 0 .68%  1.15%  
T ab le  8 P r im ar y R e aso n fo r  P r e m at u r e  C e ssat io n o f S t u dy M e dic at io n (E S P S - Z 
S t u dy)2 6
” 
P lac e b o  A S A  D P  D P -  p- V alu e  
A S A  (T r e at m e nt  
G r o u ps O ve r all 
C o m par iso n) 
N u m b e r  o f pat ie nt s in e ac h gr o u p 1,649 1,649 1,654 1,650  
N u m b e r  o f c e ssat io ns 360  366 485 479 p<0 .0 0 1 
R e aso ns fo r  c e ssat io n (m e dic al) 2 75 2 90  385 398‘ p<0 .0 0 1 
A ny adve r se  e ve nt s 1 12 7 141 2 49 2 62  p<0 .0 0 1 
G ast r o int e st inal e ve nt  60  61 10 2  116 p<0 .0 0 1 
H e adac he  39 31 132  133 p<0  .0 0 1 
Ble e ding any sit e , any se ve r it y 5 2 0  3 2 1 p<0 .0 0 1 
O t he r  m e dic al r e aso n 148 149 136 136 N S  
N o n- m e dic al 81 72  95 79 N S  
U nkno wn 4 4 5 2 -  
1 O ne  pat ie nt  m ay have  had o ne  o r  m o r e  adve r se  e ve nt s.
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A  b e ne fit  o f fam o t idine , as c o m par e d wit h plac e b o , in pr e ve nt ing b o t h G U  and D U  in 
pat ie nt s wit h ar t hr it is who  r e c e ive d N S A I D s fo r  2 4 we e ks has also  b e e n pu b lishe d?9 
H o w e ve r , t he  do se  r e qu ir e d t o  pr o du c e  o nly m o de st  b e ne fit  was high (40 m g give n t wic e a 
day) m aking t he  c o st s o f su c h t r e at m e nt  c o nside r ab le . A r e c e nt  r e vie w  o f t he  e vide nc e  b y 
W o lfe  e t  al.4° c o nc lu de d t hat  t he  u se  o f H z- r e c e pt o r  ant ago nist s fo r  t he  pr e ve nt io n o f N S A I D —  
asso c iat e d u lc e r s c anno t  b e  r e c o m m e nde d. 
b ) P r o t o n P u m p I nhib it o r s 
O m e pr azo le  and lanso pr azo le  ar e  lic e nse d fo r  t he  pr e ve nt io n o f N S A I D - indu c e d G U  o r  
D U .41 O ne  st u dy in pat ie nt s t aking N S A I D s sho w e d o m e pr azo le  t o  he al and pr e ve nt  u lc e r s 
m o r e  e ffe c t ive ly t han did r anit idine  o ve r  a six m o nt h pe r io d.42  N o  st u die s w e r e  ide nt ifie d t hat  
have  asse sse d spe c ific ally t he  e ffic ac y o f P P I  pr o phylaxis in pat ie nt s t aking lo ng- t e r m  lo w  
do se  aspir in. 
c ) O t he r  A c id S u ppr e ssant  T he r apy 
M iso pr o st o l is lic e nse d fo r  u se  in t he  pr o phylaxis o f N S A I D  indu c e d G U  and D U , ho w e ve r , 
no  st u die s o n t he  e ffic ac y o f lo ng- t e r m  lo w - do se  A S A  w e r e  fo u nd. 
c l) C o m par iso n o f E ffe c t ive ne ss b e t w e e n D iffe r e nt  A c id S u ppr e ssant  T r e at m e nt s 
T w o  R C T s c o m par e d o m e pr azo le  wit h m iso pr o st o l and plac e b o ,43 and o m e pr azo le  wit h 
r anit idine 42  in pat ie nt s wit h e st ab lishe d N S A I D  pe pt ic  u lc e r s and e r o sio ns. I n o ne  st u dy, 61%  
o f o m e pr azo le  pat ie nt s r e m aine d in r e m issio n aft e r  six m o nt hs, c o m par e d wit h 48%  o f 
m iso pr o st o l pat ie nt s and 2 7%  o f plac e b o  pat ie nt s. I n t he  se c o nd st u dy, 72 %  o f o m e pr azo le  
pat ie nt s and 59%  o f r anit idine  we r e  st ill in r e m issio n at  six m o nt hs. 
I n addit io n, a m e t a- analysis o f t r ials c o m par e d m iso pr o st o l o r  H 2 A s in t he  pr e ve nt io n o f 
N S A I D — indu c e d G I  dam age .36 
. 2 0 0 - 80 0  m ic r o gr am s o f m iso pr o st o l signific ant ly r e du c e d t he  r at e  o fG U s b y 8%  in lo ng—  
t e r m  u se , c o m par e d t o  plac e b o  (N u m b e r s ne e de d t o  t r e at  (N N T ): 12 .5). 
o  H zA s did no t  r e du c e  t he  r at e  o f G U s c o m par e d t o  plac e b o . 
0  Bo t h dr u gs we r e  c o m par ab le  fo r  D U s (N N T : m iso pr o st o l 2 9, H ZA  42 ). 
0  O ne  sho r t - t e r m  st u dy o f m iso pr o st o l 10 0  m ic r o gr am s daily ve r su s plac e b o  in he alt hy 
vo lu nt e e r s t aking 30 0 m g A S A  daily fo r  fo u r  we e ks19 indic at e d t hat  t he r e  was a 
signific ant  r e du c t io n in gast r ic  e r o sio ns in t he  m iso pr o st o l gr o u p.
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4. E C O N O M I C  A N A L Y S I S  
4.1 M E T H O D S  F O R  E C O N O M I C  A N A L Y S I S  
P ape r s c o nt aining e c o no m ic  and c o st  t e r m s w e r e  filt e r e d fr o m  t he  o r iginal lit e r at u r e  s ar c h. 
O t he r  pape r s w e r e  fo u nd as c it at io n r e fe r e nc e s in t he  c o u r se  o f r e se ar c hing t his r e po r t . T he  
se ar c h fo u nd a nu m b e r  o f pape r s, whic h w e r e  e it he r  pr im ar ily r e po r t ing t he  r e su lt s o f e c o no m ic  
e valu at io ns, o r  m ade  r e fe r e nc e  t o  t he  e c o no m ic  o r  c o st ing im plic at io ns o f ant iplat e le t  t he r apie s. 
F o u r  o f t he  pape r s (C ham b e r s e t  51L ,“ S c o t t  and S c o t t ,“‘5 O st e r  e t  al.46 and K u r z e t  al.47 r e po r t  
o r iginal e c o no m ic  e valu at io ns. O t he r  pape r s fo u nd in t he  se ar c h fr e qu e nt ly c it e  t he se  pape r s. 
T w o  o f t he  pape r s t ake  a U K  pe r spe c t ive  (C ham b e r s e t  al.44 and C u r r ie “), t ho u gh t he  C u r r ie  
pape r  is c o nc e r ne d wit h c o st ing t he  b u r de n o f st r o ke  r at he r  t han t he  e c o no m ic s o f pr e ve nt io n. 
T he  pape r s b y A le xandr o v e t  al.49 and Be ne sc h e t  al.50  ar e  r e vie ws inve st igat ing t he  pr e ve nt io n 
and t r e at m e nt  o fst r o ke . T he  pape r s b y S c o t t  and S c o t t “, K u r z e t  al.47, and C ham b e r s at  al.44 
ar e  all dir e c t e d at  t he  u se  o f A S A  and D P  fo r  t he  pr e ve nt io n o f st r o ke  in N e w  Ze aland, Be lgiu m , 
and t he  U K  r e spe c t ive ly. T he  pape r  b y O st e r  e t  31.45 is a U S - b ase d analysis o f t ic lo pidine  and 
A S A , again fo r  st r o ke  pr e ve nt io n. A  pape r  pr e se nt e d b y O ve r e ll at  t he  8t h E u r o pe an S t r o ke  
C o nfe r e nc e  in A pr il 1999, has b e e n pu b lishe d as an ab st r ac t  in C e r e b r o vasc u lar  D ise ase - 51. 
T ab le  10  su m m ar ise s de t ails o f t he  pape r s ide nt ifie d b y t he  se ar c h. 
T ab le  11 su m m ar ise s t he  ke y o r iginal pape r s b y dise ase  and dr u g c at e go r ie s and sho ws t hat  
no ne  o f t he  ide nt ifie d pape r s addr e sse s t he  e c o no m ic s o f ant iplat e le t s fo r  M l o r  P A D . 
C o nse qu e nt ly, m o st  o f t he  disc u ssio n in t his se c t io n is dir e c t e d at  t he  e c o no m ic s o f st r o ke  
pr e ve nt io n.
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T ab le  11 K e y E c o no m ic s P ape r s C lassifie d b y D ise ase  and A nt iplat e le t  
D ipyr idam o le  C lo pido gr e l T ic lo pidine  
P r im ar y pr e ve nt io n 
o f st r o ke . 
S e c o nda r e ve nt io n C ham b e r s,44 
o f st r o ke ?y 
p 
S c o t t  ”'5 K u r z"'7 
O ve r e ll51 O st e r 46 
M l N /A  
P A D  N /A  
4.1.1 E st im at io n o f N e t  Be ne fit s 
T he  b e ne fit s o f t r e at m e nt  wit h ant iplat e le t s inc lu de  t he  avo idanc e  o f st r o ke  and o t he r  
ne u r o lo gic al nd vasc u lar  e ve nt s, t he  avo idanc e  o f disab ilit y, and t he  pr o lo ngat io n o f life . 
D isb e ne fit s r e su lt  as a c o nse qu e nc e  o f adve r se  dr u g r e ac t io ns. fo r  e xam ple , G I  b le e ding 
wit h A S A , and ne u t r o pe nia wit h t ic lo pidine . M any o f t he  r e po r t e d analyse s have  u se d e it he r  
de c isio n m o de lling o r  M ar ko v m o de ls t o  e st im at e  o u t c o m e s inc lu ding nu m b e r s o f avo ide d 
st r o ke s, disab le d life  ye ar s avo ide d, life  ye ar s, and qu alit y adju st e d |ife  ye ar s (Q A L Y s). 
E st im at e s o f qu alit y o f life  qu o t e d in t he  pu b lishe d pape r s ge ne r ally have  po o r  e m pir ic al 
e vide nc e  t o  su ppo r t  t he m , and so  t he r e  is c o nside r ab le  u nc e r t aint y ar o u nd t he se  e st im at e s. 
T he  r e su lt s o f t he  var io u s analyse s ar e  disc u sse d in gr e at e r  de t ail alo ngside  t he  analysis o f 
c o st - e ffe c t ive ne ss lat e r  in t his c hapt e r . 
4.1.2  E st im at io n o f N e t  C o st s 
T he  pr inc ipal c o st s t o  t he  N H S  o f ant iplat e le t  t he r apie s ar e  t he  dr u g c o st s t he m se lve s. 
P r e sc r ib ing and m o nit o r ing have  sm all c o st  im plic at io n fr o m  G P  visit s and b lo o d t e st s. I f t he  
t he r apy last s fo r  a nu m b e r  o f ye ar s, t he n t he  fu t u r e  dr u g c o st s sho u ld b e  disc o u nt e d at  an 
appr o pr iat e  r at e . T he  c o st s o f ant iplat e le t  fo r m u lat io ns we r e  pr e se nt e d in T ab le  2 . T his t ab le  
highlight s t he  r e lat ive ly o w  c o st  o f A S A  c o m par e d t o  t he  ne w e r  ant iplat e le t s. D e pe nding o n 
do sage , t he  annu al c o st  o f E C - A S A  is ab o u t  3 t im e s t hat  o f dispe r sib le  A S A . D P  is b e t w e e n 
12  and 30  t im e s m o r e  e xpe nsive  t han dispe r sib le  A S A . C lo pido gr e l is ne ar ly fo u r  t im e s m o r e  
e xpe nsive  t han D P , and t ic lo pidine  is m o r e  t han t wic e  as e xpe nsive  as C lo pido gr e l. 
T ic lo pidine  is o ve r  30 0  t im e s m o r e  e xpe nsive  t han dispe r sib le  A S A  30 0 m g. I de ally, t he  c o st s 
o f t r e at ing adve r se  dr u g r e ac t io ns sho u ld b e  inc lu de d in an e c o no m ic  appr aisal. 
T he  sc o pe  fo r  po t e nt ial savings t o  t he  N H S  c o m e s fr o m  avo ide d ho spit al t r e at m e nt  fo r  t he  
c o ndit io ns u nde r  r e vie w. A t  b e st , t his m ight  le ad t o  ac t u al r e so u r c e  savings, and sho u ld at  
le ast  fr e e  u p N H S  b e ds, t he r e b y r e du c ing wait ing t im e s, and po ssib ly pr e ve nt ing o r  de laying
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T he  m o de l in t his G u idanc e  N o t e  is a sim ple r  spr e adshe e t  ve r sio n o f t he  m o de l pr e se nt e d 
b y C ham b e r s e t  al.44 T he ir  m o de l was de ve lo pe d t o  e valu at e  t he  c o st - e ffe c t ive ne ss o f t he  
c o - fo r m u lat io n o f A S A  and D P  fo r  st r o ke  pr e ve nt io n. T he  m o de l is a M ar ko v m o de l in whic h 
t r ansit io nal pr o b ab ilit ie s ar e  allo w e d t o  var y b y age  and o t he r  fac t o r s. T he  e st im at e s fo r  
t he se  t r ansit io nal pr o b ab ilit ie s ar e  b ase d pr im ar ily o n t he  r e su lt s o f t he  E S P S - 2  st u dy. T he  
c o st s and b e ne fit s o f ant iplat e le t s ar e  m o de lle d o ve r  a 2 5- ye ar  t r e at m e nt  pe r io d fo r  a give n 
c o ho r t  o f pat ie nt s u sing qu ar t e r ly ,t im e  pe r io ds. I n t his c ase  t he  c o ho r t  is 1,0 0 0  30 - day 
su r vivo r s o f I S . T he  m o de l in t his G u idanc e  N o t e  u se s t he  sam e  assu m pt io ns as t ho se  u se d 
b y C ham b e r s e t  al.44 wit h a fe w  no t ab le  diffe r e nc e s. T he  pr im ar y aim  o f t he  au t ho r s’ 
m o de l|ing was t o  m ake  o nly pr e lim inar y e st im at e s and c o m par iso ns o f t he  c o st -  
e ffe c t ive ne ss r at io s fo r  t he  dr u gs u nde r  r e vie w  fo r  se c o ndar y pr e ve nt io n o f st r o ke . H aving 
e st ab lishe d t hat  int o le r anc e  and side - e ffe c t  assu m pt io ns had o nly a m ino r  e ffe c t  o n t he  
r e su lt ing c o st — e ffe c t ive ne ss r at io s whe n c o m par e d wit h C ham b e r s’ e st im at e s, we  pr o c e e de d 
t o  m ake  t he  fo llo wing sim plifying assu m pt io ns: 
. T r e at m e nt  is fo r  life  o r  fo r  2 5 ye ar s, whic he ve r  is t he  sho r t e r ; 
. T he  disb e ne fit s and c o st s o f side — e ffe c t s ar e  no t  m o de lle d; 
. A ll pat ie nt s ar e  assu m e d t o  b e  t o le r ant  o f t he  dr u g pr e sc r ib e d. 
O t he r  ke y assu m pt io ns in t he  m o de l inc lu de : 
. T he  pe r spe c t ive  is t hat  o f t he  U K  he alt h and so c ial c ar e  se c t o r s; 
. T he  c o ho r t  o f pat ie nt s has a m e an age  o f 70  ye ar s; 
. 31%  o f t he  c o ho r t  ar e  assu m e d disab le d fr o m  t he  init ial st r o ke ; 
. O nly fir st  r e c u r r e nc e  o f st r o ke  is c o nside r e d; 
0  C ase  fat alit y o f r e c u r r e nt  st r o ke  var ie s b y t he r apy (r e po r t e d in E S P S - Z); 
. D isab le m e nt  o f su r vivo r s o f r e c u r r e nt  st r o ke  do e s no t  var y b y t he r apy and is assu m e d t o  
b e  35.6%  o f pr e vio u sly no n- disab le d pat ie nt s. F u r t he r  disab le m e nt  c an o nly o c c u r  as a 
r e su lt  o f a r e c u r r e nt  st r o ke ; 
. R e hab ilit at io n a d ac u t e  c ar e  c o st s o f r e c u r r e nt  st r o ke  ar e  all assu m e d t o  t ake  plac e  in 
t he  sam e  qu ar t e r  in whic h t he  r e c u r r e nt  st r o ke  o c c u r s; 
0  C o st s o f c ar e  u nr e lat e d t o  m o de lle d e ve nt s ar e  no t  inc lu de d; 
a F u t u r e  c o st s ar e  disc o u nt e d at  6% ; he alt h b e ne fit s ar e  no t  disc o u nt e d. 
T he  m o de l st r u c t u r e  is illu st r at e d in t he  fo r m  o f a de c isio n t r e e  in F igu r e  2 .
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T ab le  13 O t he r  T r ansit io nal P r o b ab ilit ie s (ab so lu t e  r isks) 
. A ssu m  t io n V ar iab le  
(%  pe r  3- m o 'r 31t h c yc le ) 
S o u r c e  
P (r e c u r r e nt  st r o ke  wit ho u t  t he r apy) 
Y e ar s 1- 2  4.88 t o  1.53 E S P S - 2  
Y e ar s 3- 2 4 1.2 5 t o  2 .52  O C S P  
N o n- st r o ke  m o r t alit y pr io r  t o  r e c u r r e nt  
st r o ke  (pe r  3 m o nt h c yc le ) 
ye ar  1 (e xc  de at h b e fo r e  30  days) 5.4 t o  2  O C S P  
Y e ar s 2 — 5 1.5 O C S P  
Y e ar s 6— 15 (age  7584) 3.6 O C S P /O P C S  
Y e ar s 16- 2 5 (age  85+) 4.5 O C S P /O P C S  
M o r t alit y (all c au se  aft e r  e c u r r e nt  
st r o ke  (pe r  3 m o nt h c yc le ) 
F ir st  ye ar  age  70 - 74 2 .1 O C S P /O P C S  
F ir st  ye ar  age  75- 84 5.8 O C S P /O P C S  
F ir st  ye ar  age  85+ 12 .9 O C S P /O P C S  
S u b se qu e nt  ye ar s age  0 - 74 2 .7 O C S P /O P C S  
S u b se qu e nt  ye ar s age  75- 84 4.6 O C S P /O P C S  
S u b se qu e nt  ye ar s age  85+ 5.8 O C S P /O P C S  
S o u r c e : C ham b e r s e t  al.44 
O C S P  = O xfo r dshir e  C o m m u nit y S t r o ke  P r o je c t  
T he  ke y o u t c o m e  var iab le s fr o m  t he  m o de l ar e  nu m b e r  o f r e c u r r e nt  st r o ke s, disab ilit y- fr e e  
life  ye ar s, st r o ke - fr e e  lif ye ar s (S F L Y ), t o t al ife  ye ar s gaine d, and ne t  c o st s. T he  c o st s 
analyse d ar e  t he  c o st s o f ant iplat e le t  t r e at m e nt , ac u t e  r e hab ilit at io n, and lo ng- t e r m  c ar e  
c o st s o f st r o ke  t r e at m e nt . T he  r e hab ilit at io n a d lo ng- t e r m  c ar e  c o st s allo w  fo r  disab ilit y 
whe r e  appr o pr iat e . C o st  e st im at e s u se d b y C ham b e r s at  al.44 have  b e e n ado pt e d fo r  t he se  
var iab le s. A n N H S  and so c ial c ar e  pe r spe c t ive  is t ake n. 
H aving c o nst r u c t e d t he  m o de l, it s o u t pu t s we r e  validat e d against  C ham b e r s’ r e su lt s, and all 
c o st  var iab le s t he n inflat e d t o  ye ar  2 0 0 0  pr ic e s. T he  inflat e d t r e at m e nt  c o st  e st im at e s u se d 
in t his m o de l ar e  pr e se nt e d in T ab le  14. 
T ab le  14 M o de lle d C o st s o f S t r o ke  T r e at m e nt  
V ar iab le  C o st  E st im at e  
(E ) 
A c u t e  c ar e  o f r e c u r r e nt  S t r o ke  3,2 70  
R e hab . (disab le d: m o difie d R ankin 3- 5) 80 1 
R e hab . (no t  disab le d: m o difie d R ankin 0 — 2 ) 42  
L o ng- t e r m  c ar e  ( 3- m o nt t h disab le d) 2 ,964 
L o ng- t e r m  c ar e  ( 3- m o nt hly no n- disab le d) 2 30  
S o u r c e : C ham b e r s at  al.44 
T he  ke y r e su lt s o f m o de lling t he  c o st s and b e ne fit s o f t r e at m e nt  wit h A S A , D P , and t he ir  c o -  
fo r m u lat io n ar e  pr e se nt e d in T ab le  15.
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e ffe c t ive  t han D P  fo r  A S A  t o le r ant  pat ie nt s. T he  r e su lt  is r o b u st  in t hat  E S P S - 2  u se da 
r e lat ive ly o w  do se  o f A S A , t he r e b y po ssib ly u nde r - e st im at ing t s e ffe c t s in t he  t r ial. 
T he  m o de l also  e st im at e s t hat  t he  c o - fo r m u lat io n has an inc r e m e nt al c o st  pe r  avo ide d 
st r o ke  o f £2 ,437 c o m par e d t o  t r e at m e nt  wit h A S A  alo ne . T he  inc r e m e nt al c o st  pe r  life  ye ar  
gaine d fo r  t he  c o - fo r m u lat io n c o m par e d wit h A S A  is e st im at e d at  £1,0 52 . C ham b e r s at  al.44 
do  no t  r e po r t  c o st s pe r  life  ye ar  e xplic it ly, alt ho u gh t he y do  e st im at e  a c o st  pe r  Q A L Y  
var ying b e t w e e n £1,0 0 0  and £6,80 0  de pe nding o n a 2 5 o r  t w o  ye ar  analysis. T he ir  analysis 
assu m e d he alt h- r e lat e d qu alit y o f life  valu e s o f 0 .85 fo r  no n- disab le d su r vivo r s and 0 .39 fo r  
disab le d su r vivo r s, alt ho u gh t he  e vide nc e  fo r  t he se  figu r e s is po o r . 
T he  inc r e m e nt al c o st — e ffe c t ive ne ss analysis (C E A ) r e po r t e d ab o ve  lo o ks favo u r ab le  fo r  t he  
c o - fo r m u lat io n c o m par e d wit h A S A , ho w e ve r  t he  fo llo wing c r it ic ism s o f t he  E S P S - 2  and 
C ham b e r s’ r e su lt s ho u ld b e  c o nside r e d: 
. C ham b e r s e t  al.44 adm it  t hat  t he ir  r e su lt s ar e  se nsit ive  t o  assu m pt io ns ab o u t  b ac kgr o u nd 
r isk o f r e c u r r e nt  st r o ke , t he  R R R  o f t he r apy o n st r o ke , as we ll as t he  c o st s o f ac u t e  and 
lo ng— t e r m  st r o ke  c ar e . T r e at m e nt  pat hs r e c o m m e nde d b y an e xpe r t  pane l and no t  fr o m  
e m pir ic al e vide nc e  de t e r m ine d t he ir  c o st  e st im at e s fo r  st r o ke . P o llo c k57 has r e po r t e d 
lo w e r  c o st s fo r  st r o ke  t han t ho se  de du c e d b y t he  C ham b e r s’ pane l e xpe r t s. 
. C ham b e r s ac kno wle dge s t hat  E S P S - 2  u se d a r e lat ive ly lo w  do se  o f A S A , so  t hat  t he  
R R R  o f st r o ke  fr o m  A S A  m ay b e  u nde r - e st im at e d in t he  t r ial and t he  m o de ls.A  
se nsit ivit y analysis u nde r t ake n b y C ham b e r s e t  al.,44 inc r e asing t he  R R R  o f A S A  fr o m  
18%  t o  2 3% , inc r e ase d t he  inc r e m e nt al c o st  pe r  avo ide d st r o ke  fo r  t he  c o — fo r m u lat io n 
c o m par e d W it h A S A  fr o m  £1,90 0  in t he  five  ye ar  analysis t o  £4,70 0  (1996 st e r ling). 
o  A  t hr e e - way se nsit ivit y analysis pr e se nt e d b y C ham b e r s e t  al.,44 u sing high c o st s o f 
ac u t e  and lo ng- t e r m  c ar e  and r e du c ing t he  b ac kgr o u nd r isk o f st r o ke  b y 2 0 %  fr o m  t he  
b ase  c ase , inc r e ase s t he  c o st  pe r  Q A L Y  gaine d (c o — fo r m u lat io n ve r su s A S A  alo ne ) t o  
£10 ,50 0  fr o m  £2 ,90 0  in t he ir  five  ye ar  analysis. 
. C ham b e r s ac kno wle dge s t hat  in a pr e vio u s t u dy b y M at c har  e t  al.,58 t he  c o - fo r m u lat io n 
(A S A  70 0  t o  130 0 m g/day and D P  150 — 30 0 m g/day) was sho wn t o  b e  e ffe c t ive  in r e du c ing 
st r o ke  in pat ie nt s wit h a pr e vio u s T I A  whe n c o m par e d wit h no  t r e at m e nt , b u t  no t  
c o m par e d wit h A S A  m o no t he r apy. T he  se nsit ivit y analysis pr e se nt e d b y C ham b e r s 
sho ws t hat  u sing t he  lo w e r  95%  c o nfide nc e  int e r val valu e  fo r  R R R  o f t he  c o - fo r m u lat io n 
inc r e ase d t he  c o st  pe r  st r o ke  ave r t e d fr o m  £1,90 0  t o  £17,80 0 . U sing t his assu m pt io n is 
no t  inappr o pr iat e  if t he  M at c har  e su lt s ar e  ac c e pt e d.
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have  b e e n u se d t o  m o de l t he  e ffe c t ive ne ss o f c lo pido gr e l, t ho u gh t he  r e lat ive  r isk (R R ) o f 
st r o ke  has b e e n lo w e r e d b y 8.7%  (t hat  is, 2 5.2 %  R R R  c o m par e d wit h no  t r e at m e nt ). T he  
t hr e e — m o nt hly c o st  o f ant iplat e le t  t r e at m e nt  assu m e d t o  b e  £115.0 7 pe r  pat ie nt . 
T he  m o de l indic at e s ne t  c o st s o f £2 8.0 m  fo r  t r e at ing t he  1,0 0 0  pat ie nt  c o ho r t  fo r  a m axim u m  
o f 2 5 ye ar s. T his figu r e  is £2 .3m  m o r e  t han t r e at m e nt  wit h A S A  alo ne . T he  m o de l also  
indic at e s t hat  t he r e  w o u ld b e  350  st r o ke s and 7,151 life  ye ar s fo r  t he  c o ho r t  (5,542  S F L Y s 
and 4,546 disab ilit y— fr e e  life  ye ar s). 
C o m par ing c lo pido gr e l wit h no  t r e at m e nt , t he  inc r e m e nt al c o st s pe r  st r o ke  avo ide d and pe r  
life  ye ar  save d ar e  £2 3,760  and £11,884 r e spe c t ive ly. C o m par e d wit h A S A , t he  inc r e m e nt al 
c o st s o f c lo pido gr e l ar e  £99,72 1 pe r  st r o ke  avo ide d and £34,856 pe r  life  ye ar  gaine d. T he se  
figu r e s highlight  t he  r e lat ive ly high c o st s o f c lo pido gr e l c o m par e d wit h A S A . 
A  ve r y sim plist ic  appr o ac h t o  m o de lling c lo pido gr e l has b e e n t ake n. I t  c o u ld b e  ar gu e d t hat  
t he  ab so lu t e  e ffe c t s o f c lo pido gr e l have  b e e n u nde r - e st im at e d b e c au se  t he  8.7%  R R  
adju st m e nt  was applie d t o  t he  r e su lt s o f t he  E S P S — 2  t r ial, whic h u se d a lo w e r  do se  o f A S A  
t han t hat  u se d in t he  C A P R I E  st u dy.2  I f t his ar gu m e nt  is ac c e pt e d t he n t he  m o de l will have  
u nde r - e st im at e d t he  c o st - e ffe c t ive ne ss o f c lo pido gr e l c o m par e d t o  no  t r e at m e nt . I t sho u ld 
b e  b o r ne  in m ind t hat  t he  R R R  o f 8.7%  r e c o r de d in t he  C A P R I E  st u dy2  was a c o m b ine d 
e ve nt  r isk r e du c t io n a d no t  so le ly a st r o ke  r e du c t io n e ffe c t . 
O t he r s m ight  ar gu e  t hat  t he  m o r t alit y b e ne fit s o f c lo pido gr e l have  b e e n o ve r - e st im at e d u sing 
t his m o de l. T he  C A P R I E  st u dy2  indic at e d no  st at ist ic ally signific ant  '3“ m o r t alit y' b e ne fit s 
fr o m  c lo pido gr e l c o m par e d wit h A S A . A lt ho u gh t he  m o de lle d sc e nar io  assu m e s t hat  t he  
dir e c t  m o r t alit y r isk fo r  st r o ke  pat ie nt s t aking c lo pido gr e l is t he  sam e  as t hat  fo r  A S A  
pat ie nt s, c lo pido gr e l pat ie nt s gain so m e  m o r t alit y b e ne fit s in t he  m o de l b e c au se  o f an 
algo r it hm  linking m o r t alit y t o  st r o ke  inc ide nc e . C o nse qu e nt ly, t he  m o de l indic at e s fe w e r  
de at hs fo r  c lo pido gr e l pat ie nt s. A lt ho u gh t his assu m pt io n do e s no t  affe c t  t he  st r o ke  
avo idanc e  c o st — e ffe c t ive ne ss t im at e s, t he  life  ye ar  gain b e ne fit s o f c lo pido gr e l m ay have  
b e e n o ve r - e st im at e d. 
D u r ing t he  c o u r se  o f r e se ar c hing t his r e po r t , a c o nfe r e nc e  ab st r ac t  b y O ve r e ll e t  al.51 
r e po r t ing t he  r e su lt s o f a c o st - e ffe c t ive ne ss analysis o f c lo pido gr e l was fo u nd. T ho u gh it  has 
no t  b e e n po ssib le  t o  r e vie w  t he  o r iginal c o nfe r e nc e  pape r , t he  ab st r ac t  r e po r t s m ar ginal
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Q A L Y  r at io  t o  b e  se nsit ive  in t he  u pwar d dir e c t io n t o  t he  ‘r isk o f st r o ke ’ assu m pt io n (95%  
C I  o f $18,0 0 0  t o  $30 6,0 0 0 ). 
0  T he  c o st s o f adde d life  ye ar s have  b e e n m o de lle d, b u t  we r e  no t  we ight e d t o  allo w  fo r  
age . U K  H o spit al and C o m m u nit y H e alt h S e r vic e s (H C H S ) pe r  c apit a figu r e s c le ar ly 
indic at e  t hat  c o st s o f adde d life  ye ar s inc r e ase  signific ant ly wit h age . 
. A lt ho u gh it  c laim s t o  inc o r po r at e  a so c ie t al c o st ing analysis, t he  pape r  pr o vide s no  
e vide nc e  o f any dir e c t  o r  indir e c t  pat ie nt  c o st s. 
S o m e  o f t he se  assu m pt io ns b ias t he  O st e r  e t  al.46 analysis in favo u r  o f life  pr o lo nging 
t r e at m e nt s and, t he r e fo r e , t ic lo pidine . D e spit e  t his, t he  au t ho r s ar gu e  t hat  t he ir  analysis is 
b iase d against  t ic lo pidine  b e c au se  o f assu m pt io ns ab o u t  t he  qu alit y o f life  fo llo wing st r o ke , 
and b e c au se  t he  st r o ke  inc ide nc e  assu m pt io n u se d in t he  m o de l is r e lat ive ly lo w  fo r  t he  
U S A . T his r e po r t ’s e st im at e s fo r  t he  c o st - e ffe c t ive ne ss o f t ic lo pidine  in st r o ke  pr e ve nt io n ar e  
c o nside r ab ly highe r  t han O st e r 's,“ alt ho u gh we ll wit hin t he  se nsit ivit y analysis pr e se nt e d b y 
t he m . 
T he r e  appe ar s t o  b é a gr o wing c o nse nsu s in t he  U K  t hat  t ic lo pidine  is no t  c o st - e ffe c t ive  fo r  
t he  pr e ve nt io n o f st r o ke . T he  D r u g and T he r ape u t ic s C o m m it t e e  fo r  t he  G r e at e r  G lasgo w  
H e alt h Bo ar d A r e a, fo r  e xam ple , has no t  adde d t ic lo pidine  t o  it s fo r m u lar y b e c au se , in it s 
V ie w, as we ll as c o st ing m o r e  t han alt e r nat ive  t he r apie s, it  o ffe r s no  advant age s o ve r  o t he r  
t r e at m e nt s. 
4.3 H E A L T H  E C O N O M I C S  C O N C L U S I O N S  
T he  lit e r at u r e  se ar c h c o ndu c t e d fo r  t his G u idanc e  N o t e  fo u nd o nly e c o no m ic  e valu at io ns 
e st im at ing t he  c o st - e ffe c t ive ne ss o f ant iplat e le t s fo r  t he  se c o ndar y pr e ve nt io n o f st r o ke . T he  
e c o no m ic s o f ant iplat e le t s fo r  t he  se c o ndar y pr e ve nt io n o f M I  and P A D  we r e  no t  r e po r t e d 
and, t he r e fo r e , ar e  no t  e valu at e d in t his r e po r t . 
Base d o n t he  m o de l pr e se nt e d b y C ham b e r s at  al.,‘“ a spr e adshe e t  m o de l has b e e n b u ilt  t o  
e nab le  pr e lim inar y e st im at e s o f t he  c o st — e ffe c t ive ne ss o f ant iplat e le t s in t he  se c o ndar y 
pr e ve nt io n o f st r o ke  t o  b e  de r ive d and c o m par e d. T he  r e su lt s o f t his m o de lling w e r e  
validat e d u sing C ham b e r s' m o de l.
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5. C O N C L U S I O N S  
1. D ispe r sib le  A S A  sho u ld r e m ain t he  fir st  line  t he r apy fo r  t he  se c o ndar y pr e ve nt io n o f 
st r o ke  and o t he r  se r io u s vasc u lar  e ve nt s, in pat ie nt s at  high vasc u lar  r isk, e xc e pt  
whe r e  it  is no t  t o le r at e d. T he r e  is no  kno wn advant age  t o  u sing E C - A S A . 
2 . F u r t he r  r e se ar c h is r e c o m m e nde d in r e lat io n t o  t he  r e spo nsive ne ss o f individu als t o  
A S A , so  t hat  t he  do se  m ay b e  adju st e d t o  m axim ise  e ffic ac y and r e du c e  side - e ffe c t s. 
U nt il fac ilit ie s fo r  t e st ing A S A  do se - r e spo nsive ne ss ar e  m o r e  wide ly availab le , pr e se nt  
e vide nc e  indic at e s t he  do se  o f 75m g daily t o  o pt im ise  t he  se c o ndar y pr e ve nt io n o f 
st r o ke  and se r io u s vasc u lar  e ve nt s, whilst  m inim ising t he  r isk o f G I  side - e ffe c t s. 
3. A S A  F ailu r e / I nt o le r anc e . 
(a) A c id su ppr e ssant  t he r apy is no t  indic at e d r o u t ine ly fo r  pat ie nt s t aking A S A . 
H o w e ve r , pat ie nt s wit h a hist o r y o f u lc e r  dise ase  o r  G I  b le e d sho u ld b e  give n a 
P P I , de spit e  t he  e vide nc e  fo r  it s b e ne fit  b e ing b ase d o n N S A I D S . I ft he r e  is no  
im pr o ve m e nt  in G I  sym pt o m s, t he  ac id- su ppr e ssant  t he r apy sho u ld b e  
disc o nt inu e d. 
(b ) M R D  
is. lic e nse d fo r  u se  wit h T I A  and I S  pat ie nt s o nly. M R D  alo ne  sho u ld b e  u se d 
as se c o nd line  t he r apy fo r  T I A  and I S  pat ie nt s who  ar e  u nab le  t o  t o le r at e  A S A  (as 
it  is c he ape r  t han c lo pido gr e l). 
(c ) A s wit h M R D , t he  c o - fo r m u lat io n f M R D  and A S A  is lic e nse d fo r  T I A  and I S  
pat ie nt s o nly. I t  c anno t  b e  advo c at e d as fir st  line  t he r apy fo r  t he se  c o ndit io ns at  
t he  pr e se nt  im e . H o w e ve r , fo r  T I A  and I S  pat ie nt s who  faile d o n A S A  t he r apy 
alo ne , t he  c o — fo r m u lat io n m ay b e  c o nside r e d. 
(d) C lo pido gr e l sho u ld b e  c o nside r e d as se c o nd line  t he r apy fo r  pat ie nt s wit h M I  and 
P A D  who  ar e  u nab le  t o  t o le r at e  o r  have  faile d o n A S A . 
(e ) C lo pido gr e l sho u ld b e  c o nside r e d as t hir d line  t he r apy fo r  pat ie nt s wit h T I A  and I S  
fo r  who m  ne it he r  A S A  no r  M R D  have  b e e n su c c e ssfu l. 
4. T ic lo pidine  sho u ld no t  b e  pr e sc r ib e d as an alt e r nat ive  t o  A S A  fo r  lo ng- t e r m  t he r apy.
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A P P E N D I X: M E D L I N E  L I T E R A T U R E  S E A R C H  S T R A T E G Y  7. 
D at ab ase : M e dline  <1966 t o  P r e se nt > 
S e ar c h: 
1 t ic lo pidine / 2 6 e xp r e vie w  lit e r at u r e / 
2  t ic lo pidine .t w. 2 7 e xp c linic al t r ials/ 
3 t ic lo pidine .r w. 2 8 m e t a— analysis/ 
4 55142  85 3.r n. 2 9 e xp gu ide line s/ 
5 c lo pido gr e l.t w. 30  he alt h planning gu ide line s/ 
6 c lo pido gr e l.r w. 31 o r /2 3- 3O  
7 90 0 55 48 4m . 32  A S A / 
8 o r /1— 7 33 (ac e t ylsalic yc lic  adj ac id).t w. 
9 e c o no m ic s/ 34 A S A .t w. 
10  e xp "c o st s and c o st  analysis"/ 35 A S A .r w. 
11 e c o no m ic  valu e  o f life / 36 50  78 2 .r n. 
12  e xp e c o no m ic s, ho spit al/ 37 o r /32 - 36 
13 e xp e c o no m ic s, m e dic al/,, 38 2 2  o r  31 
14 e c o no m ic s, nu r sing/ 39 8 and 37 and 38 
15 e c o no m ic s, phar m ac e u t ic al/ 4O  8 and 2 2  and 37 
16 e xp m o de ls, e c o no m ic / 41 8 and 37 and 31 
17 e xp “fe e s and c har ge s"! 42  8 and 2 2  and 31 and 37 
18 e xp b u dge t s/ 43 D P / 
19 e c .fs. 44 D P .t w. 
2 0  (c o st  o r  c o st s o r  c o st e d o r  c o st ly o r  45 D P .r w. 
c o st ing$).t w. 46 58- 32 - 2 .r n. 
2 1 (e c o no m ic $ o r  phar m ac o e c o no m ic $ o r  47 o r /43— 46 
pr ic e $ o r  pr ic ing).t w. 48 8 o r  47 
2 2  o r /9- 2 1 49 48 and 2 2  and 37 
2 3 c linic al t r ial.pt . 50  48 and 31 and 37 
2 4 m e t a$.pt . 51 48 and 2 2  and 31 and 37 
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